Thank you, Anita. A strong business performance. In Q2, we reported sales growth of 25% and an EBITDA margin of 19%. The strong Q2 sales are due to favorable comparisons, but also underlying growth in America and EMEA, where I will show more specifics shortly. The EBITDA margin for Q2 is 19% and brings the H1 margin up to 17%, which is at level with full year 23 and aligned with our expectations.
Now, the regional segment reporting for H1 Americas was impacted by quarter to quarter timing and the outcome is reported growth for H1, with sales up 2% and organic growth up 1%. Behind this is lots of activity by the commercial team. Examples include showcasing our most recent innovations at the Supply Side West trade show and also at Digestive Disease Week in Washington, D.C. The gross profit margin in America was impacted by added resources in operations to facilitate improvements to production. The added resources involved both internal and external consultants, as well as investments in tangible equipment.
The initial results are very promising, and we are confident that the investments made will pay off in 2025 and beyond. Next is EMEA. EMEA had very strong sales in Q2, which built on strong Q1 sales. Also, H1 is now up 48% year over year. Note though, that last year we reported inventory corrections with a major EMEA account after the Covid pandemic normalization and also the insourcing of the B2C business in Sweden, which implied lower sales in Q2 last year and this year. Both have normalized, and EMEA is on top of this, showing underlying growth and has secured a few new business wins. The sales growth, with maintained high margins, implies an overall gross profit in EMEA is up by 10 million Swedish Krona in H1. APAC sales in both Q1 and Q2 have been adversely impacted by the cross-border business sales into China being significantly reduced compared to 2023. This is impacting all players in the market, including Probi. All the major accounts were exposed to timing driven by both inventory positions and launches. Despite the lower sales than last year, the competitive position of Probi has been maintained, and gross profit is noted, impacted by an adverse product mix for H1. Now, the net income for Q2 is here broken out by the various drivers and shows that the volume effect is the real underlying driver. This is in line with the comments made earlier, specifically regarding sales timing in the Americas and EMEA. Continued investment of 27 million Swedish Krona for both plant, machinery, and equipment to drive efficiencies, but also R&D projects to support the sales pipeline. On top of this, we paid our dividend of 15 million as decided by the AGM. Noted, though, that the continued strong operating cash flow of 23 million and Probi has by this maintained an overall strong cash position.
A quick look at the balance sheet. This is mainly a slide to remind you of the strong balance sheet of Probi. With this, I'd like to give back the word to Anita Johansen.